Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1 …

J Noé, R Portmann, ME Brun, C Funk - Drug metabolism and disposition, 2007 - ASPET
Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute
carriers are more and more recognized as being involved in hepatic elimination of many drugs …

Design, data analysis, and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model

A Poirier, T Lave, R Portmann, ME Brun… - Drug metabolism and …, 2008 - ASPET
The use of in vitro data for quantitative predictions of transporter-mediated elimination in
vivo requires an accurate estimation of the transporter Michaelis-Menten parameters, V max …

The need for human breast cancer resistance protein substrate and inhibition evaluation in drug discovery and development: why, when, and how?

A Poirier, R Portmann, AC Cascais, U Bader… - Drug Metabolism and …, 2014 - ASPET
Although the multiplicity in transport proteins assessed during drug development is continuously
increasing, the clinical relevance of the breast cancer resistance protein (BCRP) is still …

Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo

A Poirier, AC Cascais, U Bader, R Portmann… - Drug Metabolism and …, 2014 - ASPET
The multidrug resistance protein 1 (MDR1) is known to limit brain penetration of drugs and
play a key role in drug-drug interactions (DDIs). Theoretical cut-offs from regulatory guidelines …

Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor

T Lavé, R Portmann, G Schenker… - Journal of pharmacy …, 1999 - Wiley Online Library
The objective of this work was to assess the pharmacokinetics of napsagatran, a low
molecular weight thrombin inhibitor, after intravenous administration in a variety of laboratory …

Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir

…, S Moreira, PN Morcos, P Goelzer, R Portmann… - Clinical …, 2015 - Springer
Background and Objectives Understanding transmembrane transport provides a more complete
understanding of the pharmacokinetics of a drug and mechanistic explanations for drug–…

Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies

…, S Belli, C Funk, MB Otteneder, R Portmann… - Drug Metabolism and …, 2012 - ASPET
It was reported that oseltamivir (Tamiflu) absorption was mediated by human peptide
transporter (hPEPT) 1. Understanding the exact mechanism(s) of absorption is important in the …

The determination of a new trifluorinated quinolone, fleroxacin, its N-demethyl, and N-oxide metabolites in plasma and urine by high performance liquid …

D Dell, C Partos, R Portmann - Journal of liquid chromatography, 1988 - Taylor & Francis
A liquid chromatographic method is described for the determination of the new fluoroquinolone
Ro 23–6240 and its N-demethyl and N-oxide metabolites in plasma and urine. The three …

Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients

…, T Leemann, E Weidekamm, R Portmann… - Antimicrobial agents …, 1994 - Am Soc Microbiol
Fleroxacin is a new broad-spectrum quinolone which can be given by the oral route. The
present study was designed to assess the influence of bacteremia on the pharmacokinetics of a …

Drug‐Induced Intrahepatic Cholestasis by Interaction with the Hepatic Bile Salt Export Pump (BSEP)

C Funk, J Noé, R Portmann… - … to in vitro and in vivo …, 2007 - Wiley Online Library
Drug-induced liver disease is one of the major challenges for drug development and drug
safety. Many drugs and herbal remedies have been implicated in causing hepatic injuries, …